Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

On World No Tobacco Day, Imperial Tobacco Canada (Imperial) is calling on government, health advocates, and all Canadians to embrace?harm reduction as a key strategy to achieve a smokeless Canada in ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Altair, a global leader in computational intelligence, announced that Altair® RapidMiner®, Altair's data analytics and AI ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell ...